EW vs. STE, ISRG, ZBH, ALGN, DXCM, MRNA, COR, ALC, IDXX, and TAK
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include STERIS (STE), Intuitive Surgical (ISRG), Zimmer Biomet (ZBH), Align Technology (ALGN), DexCom (DXCM), Moderna (MRNA), Cencora (COR), Alcon (ALC), IDEXX Laboratories (IDXX), and Takeda Pharmaceutical (TAK). These companies are all part of the "medical" sector.
Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Edwards Lifesciences has higher revenue and earnings than STERIS. Edwards Lifesciences is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Edwards Lifesciences currently has a consensus price target of $93.88, suggesting a potential upside of 5.31%. STERIS has a consensus price target of $241.60, suggesting a potential upside of 3.83%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Edwards Lifesciences is more favorable than STERIS.
In the previous week, Edwards Lifesciences had 2 more articles in the media than STERIS. MarketBeat recorded 19 mentions for Edwards Lifesciences and 17 mentions for STERIS. STERIS's average media sentiment score of 0.77 beat Edwards Lifesciences' score of 0.77 indicating that STERIS is being referred to more favorably in the news media.
79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 1.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.0% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Edwards Lifesciences has a net margin of 23.01% compared to STERIS's net margin of 6.95%. Edwards Lifesciences' return on equity of 22.86% beat STERIS's return on equity.
Edwards Lifesciences received 987 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 71.82% of users gave Edwards Lifesciences an outperform vote while only 58.51% of users gave STERIS an outperform vote.
Summary
Edwards Lifesciences beats STERIS on 14 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
